Navigation Links
Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
Date:10/21/2008

NEW YORK, Oct. 21 /PRNewswire/ -- Golub Capital today announced that it has provided a GOLD facility for the acquisition of DNA Diagnostics Center, Inc. (DDC) by MTS Health Investors, LLC (MTS). GOLD financings are proprietary Golub Capital One-Loan Debt facilities. Terms of the transaction were not disclosed.

DDC, based in Fairfield, Ohio, is one of the largest and most reputable DNA testing laboratories worldwide and the market leader in human DNA identification testing for the private sector. The Company provides a wide array of DNA testing services in the fields of biological family relationships, forensics and veterinary genetics.

DDC has achieved national recognition serving as the laboratory of choice for many national media programs including Dateline, 48 Hours and Dr. Phil, and has provided the DNA testing for numerous high-profile legal disputes. These cases include the Ohio Innocence Project, which helped exonerate Robert McClendon after 18 years of incarceration, and the landmark paternity suit that identified Larry Birkhead as the biological father of Anna Nicole Smith's daughter.

This is Golub Capital's first deal with MTS. "We are pleased to be working with MTS," said Golub Capital Principal Stefano Robertson. "Golub Capital's financial resources will help strengthen DDC's position in its unique marketplace. We are looking forward to watching DDC grow internationally."

"In this difficult economic environment it is terrific to have Golub Capital as a partner. Golub followed through with its commitment even during this volatile credit market. After working with the Golub team on closing this deal, we are confident that Golub will help us grow the company as we capitalize on opportunities within the DNA testing industry," says Kenton Rosenberry, a Managing Director with MTS.

About Golub Capital

Golub Capital underwrites and syndicates 1st lien loans up to $150 million. Our buy-and-hold products range from $5 million to $75 million and include one-loan financings (through the Firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. With a broad investment mandate and long-term time horizon, Golub Capital has a high level of flexibility in structuring investments. Golub Capital is a national firm. For more information, please visit http://www.golubcapital.com.


'/>"/>
SOURCE Golub Capital
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
2. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
3. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
4. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
5. Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
6. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
7. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
8. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
(Date:6/22/2016)... June 22, 2016 Research and Markets has ... report to their offering. ... 2014 from $29.3 billion in 2013. The market is expected to ... from 2015 to 2020, increasing from $50.6 billion in 2015 to ... forecasts during the forecast period (2015 to 2020) are discussed. As ...
(Date:6/22/2016)... --  ViaCyte, Inc. , a privately-held regenerative medicine company ... for the treatment of diabetes in clinical-stage development, today ... 2016, the Global Stem Cell Event, is taking place ... Francisco.    ... Focus Session: Tools for Basic and Applied Stem Cell ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):